Search
EHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Bleeding and thrombosis
EHA Guidelines on management of antithrombotic treatments…
Highlights from the SWG
The European Scientific foundation for Laboratory Hemato Oncology (ESLHO), together with the three scientific consortia of EuroClonality, EuroMRD, and EuroFlow, share the same four goals:
Research and innovation of diagnostic patient care
Standardization of laboratory diagnostics
Quality assessment
Education
ESLHO supports the three consortia in…
EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)
On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.
Read moreKiller antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreEHA-BMAH Joint Membership
Join EHA and BMAH to receive up to €80 discount on your membershipThe European Hematology Association (EHA) and the Bulgarian Medical Society of Hematology (BMAH), have joined forces to offer joint membership to their members.
Read moreEHA-AHK Joint Membership
Join EHA and AHK to receive up to €80 discount on your membershipThe European Hematology Association (EHA) and the Asociacioni i Hematologëve të Kosovës (AHK), have joined forces to offer joint membership to their members.
Read moreEHA-HSH Joint Membership
Join EHA and HSH to receive up to €50 discount on your membershipThe European Hematology Association (EHA) and the Hellenic Society of Haematology (HSH), have joined forces to offer joint membership to their members.
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- »